

# Troglitazone

Catalog No: tcsc1634



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

97322-87-7

**Formula:**

$C_{24}H_{27}NO_5S$

**Pathway:**

Cell Cycle/DNA Damage;Autophagy

**Target:**

PPAR;Autophagy

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq$  100 mg/mL (226.48 mM)

**Alternative Names:**

CS-045

**Observed Molecular Weight:**

441.54


## Product Description

Troglitazone is a **PPAR $\gamma$**  agonist, with **EC<sub>50</sub>**s of 550 nM and 780 nM for human and murine PPAR $\gamma$  receptor, respectively.

IC50 & Target: EC50: 550 nM (Human PPAR $\gamma$ ), 780 nM (Murine PPAR $\gamma$ )<sup>[1]</sup>

**In Vitro:** Troglitazone is a **PPAR $\gamma$**  agonist, with EC<sub>50</sub>s of 550 nM and 780 nM for human and murine PPAR $\gamma$  receptor, respectively<sup>[1]</sup>. Troglitazone (2-200  $\mu$ M) is cytotoxic to the pancreatic cancer cell lines (MIA Paca2 and PANC-1 cells), with IC<sub>50</sub>s of  $49.9 \pm 1.2$  and  $51.3 \pm 5.3$   $\mu$ M, respectively. Troglitazone (50  $\mu$ M) increases chromatin condensation in MIA Paca2 and PANC-1 cells, enhances the activity of caspase-3 and decreases Bcl-2 expression<sup>[2]</sup>. Troglitazone (0, 1, 2, and 4  $\mu$ M) sensitizes TRAIL-mediated apoptosis in human lung adenocarcinoma cells. Troglitazone enhancement of TRAIL-induced apoptosis is blocked by inhibition of autophagy, via activation of autophagy flux. In addition, the effects of troglitazone are induced by PPAR $\gamma$  activation in A549 cells<sup>[3]</sup>.

**In Vivo:** Troglitazone (200 mg/kg, p.o.) shows inhibitory effects on the growth of tumor in the MIA Paca2 xenograft model<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!